Cargando…

Glucagon Receptor Signaling and Glucagon Resistance

Hundred years after the discovery of glucagon, its biology remains enigmatic. Accurate measurement of glucagon has been essential for uncovering its pathological hypersecretion that underlies various metabolic diseases including not only diabetes and liver diseases but also cancers (glucagonomas). T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janah, Lina, Kjeldsen, Sasha, Galsgaard, Katrine D., Winther-Sørensen, Marie, Stojanovska, Elena, Pedersen, Jens, Knop, Filip K., Holst, Jens J., Wewer Albrechtsen, Nicolai J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651628/ https://www.ncbi.nlm.nih.gov/pubmed/31284506 http://dx.doi.org/10.3390/ijms20133314

Ejemplares similares

Glucagon Receptor Signaling and Lipid Metabolism
por: Galsgaard, Katrine D., et al.
Publicado: (2019)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice
por: Galsgaard, Katrine D., et al.
Publicado: (2022)

Methods and Guidelines for Measurement of Glucagon in Plasma
por: Holst, Jens J., et al.
Publicado: (2019)

The Liver–α-Cell Axis in Health and in Disease
por: Richter, Michael M., et al.
Publicado: (2022)

Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells
por: Elmelund, Emilie, et al.
Publicado: (2022)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism
por: Kjeldsen, Sasha A S, et al.
Publicado: (2021)

Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis
por: Winther-Sørensen, Marie, et al.
Publicado: (2020)

Molecular and in vivo phenotyping of missense variants of the human glucagon receptor
por: van der Velden, Wijnand J.C., et al.
Publicado: (2021)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
por: Ronn, Jonas, et al.
Publicado: (2017)

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia
por: Lobato, Carolina B., et al.
Publicado: (2020)

Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
por: Kjeldsen, Sasha A S, et al.
Publicado: (2023)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation
por: Larger, Etienne, et al.
Publicado: (2016)

GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass
por: Guimarães, Marta, et al.
Publicado: (2015)

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass
por: Tharakan, George, et al.
Publicado: (2017)

The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease
por: Galsgaard, Katrine D.
Publicado: (2020)

Acute administration of interleukin‐6 does not increase secretion of glucagon‐like peptide‐1 in mice
por: Christiansen, Charlotte B., et al.
Publicado: (2018)

A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats
por: Hoelmkjaer, Kirsten M., et al.
Publicado: (2016)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
por: Subramanian, Vijaya, et al.
Publicado: (2022)

SAT037 Glucagon-like Peptide-1 Receptor Knockout Mice Do Not Compensate For The Lack Of Incretin Action By Increasing Glucose-dependent Insulinotropic Polypeptide Secretion
por: Douglas Galsgaard, Katrine, et al.
Publicado: (2023)

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
por: Hædersdal, Sofie, et al.
Publicado: (2020)

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
por: Christensen, Mikkel, et al.
Publicado: (2011)

Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R–dependent manner
por: Jepsen, Sara L., et al.
Publicado: (2021)

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
por: Hare, Kristine J., et al.
Publicado: (2010)

Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
por: Holst, Jens Juul
Publicado: (2022)

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014)

Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study
por: Hansen, Nina L., et al.
Publicado: (2020)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
por: Ørgaard, Anne, et al.
Publicado: (2017)

Insulin and Glucagon: Partners for Life
por: Holst, Jens Juul, et al.
Publicado: (2017)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

High‐Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta‐Adrenoceptor Blockade: A Randomized Clinical Trial
por: Petersen, Kasper M., et al.
Publicado: (2020)

Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
por: Asmar, Ali, et al.
Publicado: (2017)

The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Postprandial Insulin Secretion After Gastric Bypass Surgery: The Role of Glucagon-Like Peptide 1
por: Holst, Jens Juul
Publicado: (2011)

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
por: Foghsgaard, Signe, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_98j3r7ibk65djojhtrnbk5j0da